CND Life Sciences
Pioneering cutaneous neurodiagnostic solutions to advance patient care.
Pioneering cutaneous neurodiagnostic solutions to advance patient care.
CND Life Sciences is a biotechnology startup dedicated to advancing patient care for those suffering from neurodegenerative diseases. Based in Scottsdale, AZ, the company operates a CLIA-certified and CAP-accredited laboratory and has developed the Syn-One Test®. This test is the first of its kind, offering a minimally invasive way to detect and quantify the presence of misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers, aiding in the diagnosis of conditions such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure.
The company, founded in 2017, has garnered interest from investors, with the latest Venture - Series Unknown investment occurring on 27 March 2024. CND Life Sciences also collaborates with several biopharmaceutical companies, furthering its commitment to advancing science in the field of neurodiagnostics. With its pioneering approach and strategic alliances, CND Life Sciences aims to make a significant impact in the biotechnology, healthcare, and life sciences industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture - Series Unknown | Unknown | - | 27 Mar 2024 | |
| Seed | Unknown | - | 24 Mar 2023 | |
| Grant | Unknown | - | 06 Oct 2022 | |
| Grant | Unknown | - | 18 May 2022 | |
| Seed | Unknown | - | 01 Feb 2022 |
No recent news or press coverage available for CND Life Sciences.
We care about your data, and we'd love to use cookies make your experience better.
